Phileo Lesaffre unveils new tilapia farming functional nutrition program

By Jane Byrne contact

- Last updated on GMT

© GettyImages/EasyBuy4u
© GettyImages/EasyBuy4u

Related tags: Yeast, Phileo Lesaffre, tilapia, disease challenge

The initiative, said the functional yeast producer, is aimed at improving tilapia gut health and support disease prevention strategies.

“The Program Aquasaf Tilapia was conceived to maximize productivity, profitability and sustainability of tilapia farming using Phileo’s functional yeast probiotics and postbiotics.

"To build the program, Phileo draws on knowledge from more than 10 R&D projects carried out in China, Thailand, Vietnam, Brazil, Mexico, and the Philippines using different products and their combination, both in lab and field conditions.”

Oxidative stress

The project is designed to provide science-based recommendations to deal with challenges faced by producers such as mortalities caused by bacterial infections from Aeromonas hydrophila​ and Streptococcus agalactiae​, reduced growth associated with oxidative stress, economic losses due to poor gut health and feed conversion, while avoiding the use of antimicrobial and chemical substances.  

“We designed the program to provide a clear view on the mechanisms of action of our solutions and their benefits on immunity, microbiota and performance in different production conditions.

"It is a tool to support and empower professionals when developing preventive care strategies for a more sustainable tilapia production,”​ said Otavio Serino Castro, Phileo’s aquaculture global species manager.

Intensification of farming 

Tilapia is farmed in many subtropical regions, such as China, Egypt, and Brazil where production is hindered by seasonal diseases, hence specific actions throughout the production cycle are needed, said the producer.

In certain production areas, such production constraints are only like to increase in complexity due to the continued development and intensification of farming, water scarcity, the emergence of antimicrobial-resistant pathogens and climate change, added the firm.

Related topics: R&D

Related news

Show more